Skip to main content
CVRX
NASDAQ Industrial Applications And Services

CVRx Appoints John Landry as CFO with $500K Salary and 0.80% Equity Grant

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Medical Device Stocks · Healthcare
Sentiment info
Neutral
Importance info
7
Price
$2.97
Mkt Cap
$79.126M
52W Low
$2.2
52W High
$11.3
52W Position info
35% above low
Off High info
74% below high
Rel. Volume info
0.4× avg
Market data snapshot near publication time

CVRX sits 35% above its 52-week low of $2.2 on light trading volume (0.4× avg).

Summary

CVRx appointed John Landry as CFO effective October 12, 2026, with a $500,000 salary, 50% target bonus, and equity awards representing 0.80% of outstanding shares. He succeeds Jared Oasheim, whose resignation was previously announced.


Key Events · Executive and Board Changes · CVRX

  • New CFO Appointed

    John Landry has been appointed CFO, succeeding Jared Oasheim. Landry joins on October 12, 2026, and assumes CFO duties the day after the Q3 2026 Form 10-Q filing, expected in early November 2026.

  • Compensation Package

    Landry will receive a $500,000 annual base salary, a 50% target cash bonus pro-rated for fiscal 2026, and equity awards representing 0.80% of outstanding shares, split 75% stock options and 25% RSUs at a 1.5:1 multiple.

  • Leadership Transition

    Oasheim's resignation was previously disclosed on June 8, 2026. He will remain for a transition period consistent with his transition agreement.

  • Activist Pressure Context

    The appointment follows activist investor Jorey Chernett's August 2026 demand for a sale process and a securities fraud investigation announced by Hagens Berman in August 2026.


Analysis · CVRX · Industrial Applications And Services

CVRx has appointed John Landry as its new CFO, filling a critical leadership gap left by the prior CFO's resignation in June. Landry brings two decades of medtech finance experience, including CFO roles at Nyxoah and Vapotherm. His compensation package includes a $500,000 base salary, a 50% target bonus, and equity awards representing 0.80% of outstanding shares. The appointment comes amid activist pressure for a sale process and a recent securities fraud investigation, making the CFO hire a key step in stabilizing the company's financial leadership.

How filings like this one have moved

In the 30 days to Nov 12, 2026, 37% of the 3595 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, CVRX was trading at $2.97 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $79.1M. The 52-week trading range was $2.20 to $11.30. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

CVRX - Latest Insights

CVRX
Nov 05, 2026, 4:17 PM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $1.47
Real-time Price: $0.590 info
Change: -$0.880 (-60%) info
Market Cap: $17.302M info
CVRX
Nov 05, 2026, 4:10 PM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $1.47
Real-time Price: $0.590 info
Change: -$0.880 (-60%) info
Market Cap: $17.302M info
CVRX
Nov 05, 2026, 4:05 PM EST
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $1.47
Real-time Price: $0.590 info
Change: -$0.880 (-60%) info
Market Cap: $17.302M info
CVRX
Oct 02, 2026, 9:30 PM EDT
Filing Type: SCHEDULE 13D/A
Importance Score:
8
Price at Filing: $1.53
Real-time Price: $0.590 info
Change: -$0.940 (-61%) info
Market Cap: $17.302M info
CVRX
Aug 24, 2026, 8:00 PM EDT
Filing Type: SCHEDULE 13D
Importance Score:
8
Price at Filing: $3.12
Real-time Price: $0.590 info
Change: -$2.53 (-81%) info
Market Cap: $17.302M info